News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a brief "earnings snapshot" for NovoCure's Q2 performance. Due to the limited content, specific financial details are not available.
NovoCure (NASDAQ: NVCR) reported a 16% year-over-year increase in Q2 2026 revenue, reaching $183.6 million, driven by an 18% growth in active patients and international market expansion. The company's Adjusted EBITDA turned positive at $10.8 million, indicating improving operating leverage. Key developments include FDA …
NovoCure reported record net revenues of $184 million in Q2 2026, a 16% year-over-year increase, driven by growth in Optune Gio, Lua, and Pax, with an 11% rise in active Optune Gio patients. The company updated its full-year revenue guidance to $710-$725 million and …
Novocure stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment, Optune. Continue Reading
Novocure (NASDAQ: NVCR) is set to report its second-quarter earnings, with investor attention focused on the early performance of its newly launched Optune Pax therapy for pancreatic cancer. The company aims for this therapy to become its second major revenue generator, complementing its existing …
Novocure Inc. recently disclosed $160,000 in lobbying expenditures for Q2 2026, focusing on medical device tariff issues and patient access to breakthrough products. Insider trading activity for NVCR shows 17 sales and no purchases in the last six months, with several executives selling shares. …
NovoCure (NVCR) has shown mixed stock performance recently, with short-term gains against longer-term declines. Despite its current share price of $15.92, a prevailing narrative suggests the company is 38.9% undervalued, with a fair value of $26.07, based on potential growth from new TTFields therapy …
Novocure (NVCR) is scheduled to announce its financial results pre-market on July 23. Analysts estimate the company will report a quarterly loss of $0.34 per share and revenue of $137.95 million. The report will provide insights into the company's financial performance and future outlook.
NovoCure (NVCR) is expected to report a narrower loss compared to the previous year, with revenues also projected to increase for the quarter ending June 2026. However, despite a positive earnings ESP, the company's Zacks Rank of #4 makes it difficult to definitively predict …
Search by ticker symbol or company name and select a result to open its chart.